FEBUTEX-40MG

About

FEBUTEX-40MG contains Febuxostat, a potent and selective non-purine inhibitor of xanthine oxidase. This enzyme is pivotal in the purine metabolism pathway, catalyzing the sequential oxidation of hypoxanthine to xanthine and then to uric acid, which is the final metabolic product. By effectively inhibiting xanthine oxidase, Febuxostat significantly reduces the production of uric acid within the body, thereby leading to a substantial decrease in serum uric acid levels. This action is critically important in the long-term management of chronic hyperuricemia in patients diagnosed with gout. Sustained high uric acid levels can precipitate the formation of urate crystals in joints and other tissues, triggering painful and debilitating gout flares. The 40mg dosage is a common starting point, carefully titrated to achieve target serum uric acid levels and prevent recurrent gout attacks, improving patient quality of life.

Uses

• Management of chronic hyperuricemia in patients with gout.
• Prevention of gout flares.
• Reduction of serum uric acid levels.
• Dissolution of urate crystals in joints.

Directions For Use

Take FEBUTEX-40MG orally once daily, with or without food, as directed by your physician. Do not stop taking it during gout flares, as this may worsen the condition.

Benefits

• Effectively lowers serum uric acid levels.
• Reduces the frequency and severity of gout flares.
• Helps dissolve existing urate crystals.
• Improves long-term management of gout.
• Convenient once-daily dosing.
• Well-tolerated by many patients.

Side Effects

• Nausea
• Diarrhea
• Headache
• Dizziness
• Rash
• Abnormal liver function tests
• Gout flares (initial treatment)
• Joint pain
• Muscle pain
• Fatigue
• Edema
• Cardiac events (rare, but noted in some studies)

Safety Measures

• Alcohol - Excessive alcohol consumption can increase uric acid levels and may counteract the effects of FEBUTEX-40MG. Moderate intake is generally advised.
• Pregnancy - FEBUTEX-40MG is not recommended during pregnancy due to insufficient data on human safety. Use only if the potential benefit justifies the potential risk to the fetus.
• Breastfeeding - It is unknown if Febuxostat is excreted in human milk. Breastfeeding is not recommended during treatment with FEBUTEX-40MG.
• Liver - Use with caution in patients with mild to moderate hepatic impairment. Regular monitoring of liver function tests is recommended. Not recommended in severe hepatic impairment.
• Kidney - No dose adjustment is required for mild to moderate renal impairment. Caution is advised in severe renal impairment, and close monitoring is recommended.
• Lung - Generally safe for use in patients with lung conditions. No specific precautions are usually needed unless there are severe underlying comorbidities.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.